Lantheus Holdings (LNTH) Asset Writedowns and Impairment (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Asset Writedowns and Impairment came in at $1.5 million in Q1 2026, up 211.54% year-on-year from $493358.0 in Q1 2025, and up 330.43% on a QoQ basis from -$667000.0 in Q4 2025.
Lantheus Holdings (LNTH) Asset Writedowns and Impairment (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Asset Writedowns and Impairment data on file, last reported at $1.5 million in Q1 2026.
- On a quarterly basis, Asset Writedowns and Impairment rose 211.54% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $5.1 million, a 223.75% increase from a year earlier, with the FY2025 full-year figure at $2.2 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q1 2026 stood at $1.5 million, up from -$667000.0 in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for LNTH reached as high as $132.1 million in Q1 2023 and fell as low as -$1.4 million in Q1 2025.
- Historically, Asset Writedowns and Impairment has averaged $12.4 million across 5 years, with a median of $1.7 million in 2025.
- Across the five-year window, Asset Writedowns and Impairment soared 3680.42% in 2022 and sank 149.98% in 2025, its largest moves.
- Year by year, Asset Writedowns and Impairment stood at $7.1 million in 2022, then slipped by 16.05% to $6.0 million in 2023, then plunged by 112.3% to -$738000.0 in 2024, then gained by 9.62% to -$667000.0 in 2025, then jumped by 330.43% to $1.5 million in 2026.
- Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $1.5 million in Q1 2026, -$667000.0 in Q4 2025, and $1.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.74 Bn | 86.88 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.87 Bn | 32.13 Bn | 1.97 Bn |
| 3 | Zoetis | 32.28 Bn | 30.34 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.14 Bn | 20.98 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.89 Bn | 16.57 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn |
| 10 | Lantheus Holdings | 7.02 Bn | 6.53 Bn | 230.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.54 Mn |
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | -667,000.00 |
| Dec 31, 2025 | -667,000.00 |
| Sep 30, 2025 | 1.93 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Mar 31, 2025 | -1.38 Mn |
| Mar 31, 2025 | -1.38 Mn |
| Dec 31, 2024 | -738,000.00 |
| Dec 31, 2024 | -738,000.00 |
| Sep 30, 2024 | -1.19 Mn |
| Sep 30, 2024 | -1.19 Mn |
| Jun 30, 2024 | -832,000.00 |
| Jun 30, 2024 | -832,000.00 |
| Mar 31, 2024 | 2.76 Mn |
| Mar 31, 2024 | 2.76 Mn |
| Jun 30, 2023 | 6.00 Mn |
| Jun 30, 2023 | 6.00 Mn |